Stay updated on Pembrolizumab/Lenvatinib vs Docetaxel in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab/Lenvatinib vs Docetaxel in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab/Lenvatinib vs Docetaxel in NSCLC Clinical Trial page
- Check6 days agoChange DetectedUI updates include a glossary toggle, color-coded highlights for additions and deletions, and a revision banner showing v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedRevision tag updated from v3.3.3 to v3.3.4 in the page footer, with no changes to study data or record content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check48 days agoChange DetectedAdded Revision: v3.3.3 and removed HHS Vulnerability Disclosure and Revision: v3.3.2.SummaryDifference0.1%

- Check69 days agoChange DetectedRevision history now shows an addition of Revision: v3.3.2 and removal of Revision: v3.2.0.SummaryDifference0.0%

- Check76 days agoChange DetectedThe page removed a government funding notice, which is a minor administrative change and does not affect the study record or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check99 days agoChange DetectedA new version entry was added to the Record History, showing an updated submission date. No core study data appear to be altered.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab/Lenvatinib vs Docetaxel in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab/Lenvatinib vs Docetaxel in NSCLC Clinical Trial page.